Review of therapeutic options and the management of patients with myelodysplastic syndromes

References

• Mufti G, List AF, Gore SD, Ho AY. Myelodysplastic syndrome. Hematology Am. Soc. Hematol. Educ. Program 176–199 (2003).
   PubMedGoogle Scholar
• Cazzola M, Malcovati L. Myelodysplastic syndromes – coping with ineffective hematopoiesis. N. Engl. J. Med. 352(6), 536–538 (2005).
   PubMed Web of Science ®Google Scholar
• Cazzola M, Della Porta MG, Malcovati L. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Hematology Am. Soc. Hematol. Educ. Program 166–175 (2008).
   PubMed Web of Science ®Google Scholar
• Intragumtornchai T, Rojnukkarin P, Swasdikul D, Vajanamarhutue C, Israsena S. Anemias in Thai patients with cirrhosis. Int. J. Hematol. 65(4), 365–373 (1997).
   PubMed Web of Science ®Google Scholar
• Barzi A, Sekeres MA. Myelodysplastic syndromes: a practical approach to diagnosis and treatment. Cleve. Clin. J. Med. 77(1), 37–44 (2010).
   PubMed Web of Science ®Google Scholar
• Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat. Rev. Cancer 7(2), 118–129 (2007).
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vardiman JW. Myelodysplastic syndromes. N. Engl. J. Med. 361(19), 1872–1885 (2009).
   PubMed Web of Science ®Google Scholar
• Stevenson W, Garcia-Manero G. Myelodysplastic syndromes. In: Leukemias: Principles and Practice of Therapy. Faderl S and Kantarjian H (Eds). Wiley–Blackwell, Oxford, UK (2010).
   Google Scholar
• Mhawech P, Saleem A. Myelodysplastic syndrome: review of the cytogenetic and molecular data. Crit. Rev. Oncol. Hematol. 40(3), 229–238 (2001).
   PubMed Web of Science ®Google Scholar
• Sekeres MA. The myelodysplastic syndromes. Expert Opin. Biol. Ther. 7(3), 369–377 (2007).
   PubMed Web of Science ®Google Scholar
• Aul C, Bowen DT, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 83(1), 71–86 (1998).
   PubMed Web of Science ®Google Scholar
• Aul C, Giagounidis A, Germing U. Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int. J. Hematol. 73(4), 405–410 (2001).
   PubMed Web of Science ®Google Scholar
• Rollison DE, Howlader N, Smith MT et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 112(1), 45–52 (2008).
   PubMed Web of Science ®Google Scholar
• Meytes D, Chodick G, Shalev V, Porath A. The long term risk of myelodysplastic syndromes among anemia patients: a population-based study. Leuk. Res. 36(3), 327–330 (2012).
   PubMed Web of Science ®Google Scholar
• Maynadié M, Verret C, Moskovtchenko P et al. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br. J. Cancer 74(2), 288–290 (1996).
   PubMed Web of Science ®Google Scholar
• Komrokji R. Myelodysplastic syndromes: a view from where the sun rises and where the sun sets. Leuk. Res. 30(9), 1067–1068 (2006).
   PubMed Web of Science ®Google Scholar
• Matsuda A, Germing U, Jinnai I et al. Differences in the distribution of subtypes according to the WHO classification 2008 between Japanese and German patients with refractory anemia according to the FAB classification in myelodysplastic syndromes. Leuk. Res. 34(8), 974–980 (2010).
   PubMed Web of Science ®Google Scholar
• Cogle CR, Craig BM, Rollison DE, List AF. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood 117(26), 7121–7125 (2011).
   PubMed Web of Science ®Google Scholar
• Irons RD, Wang X, Gross SA et al. Prevalence of MDS subtypes in Shanghai, China: a comparison of the World Health Organization and French American British classifications. Leuk. Res. 30(7), 769–775 (2006).
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee JH, Shin YR et al. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia 17(2), 305–313 (2003).
   PubMed Web of Science ®Google Scholar
• Matsuda A, Germing U, Jinnai I et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood 106(8), 2633–2640 (2005).
   PubMed Web of Science ®Google Scholar
• Chen B, Zhao WL, Jin J et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in western countries. Leukemia 19(5), 767–775 (2005).
   PubMed Web of Science ®Google Scholar
• Toyama K, Ohyashiki K, Yoshida Y et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia 7(4), 499–508 (1993).
   PubMed Web of Science ®Google Scholar
• Oguma S, Yoshida Y, Uchino H, Maekawa T, Nomura T, Mizoguchi H; Anemia Study Group of the Ministry of Health and Welfare. Clinical characteristics of Japanese patients with primary myelodysplastic syndromes: a co-operative study based on 838 cases. Leuk. Res. 19(3), 219–225 (1995).
   PubMed Web of Science ®Google Scholar
• Matsushima T, Handa H, Yokohama A et al. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood 101(9), 3386–3390 (2003).
   PubMed Web of Science ®Google Scholar
• Germing U, Gattermann N, Strupp C, Aivado M, Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk. Res. 24(12), 983–992 (2000).
   PubMed Web of Science ®Google Scholar
• Haase D, Germing U, Schanz J et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110(13), 4385–4395 (2007).
   PubMed Web of Science ®Google Scholar
• Fenaux P. Chromosome and molecular abnormalities in myelodysplastic syndromes. Int. J. Hematol. 73(4), 429–437 (2001).
   PubMed Web of Science ®Google Scholar
• Heim S. Cytogenetic findings in primary and secondary MDS. Leuk. Res. 16(1), 43–46 (1992).
   PubMed Web of Science ®Google Scholar
• Rigolin GM, Cibien F, Martinelli S et al. Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with 'normal' FISH: correlations with clinicobiologic parameters. Blood 119(10), 2310–2313 (2012).
   PubMed Web of Science ®Google Scholar
• Padron E, Komrokji R, List AF. Biology and treatment of the 5q- syndrome. Expert Rev. Hematol. 4(1), 61–69 (2011).
   PubMed Web of Science ®Google Scholar
• Boultwood J, Pellagatti A, Cattan H et al. Gene expression profiling of CD34+ cells in patients with the 5q syndrome. Br. J. Haematol. 139(4), 578–589 (2007).
   PubMed Web of Science ®Google Scholar
• Boultwood J, Lewis S, Wainscoat JS. The 5q-syndrome. Blood 84(10), 3253–3260 (1994).
   PubMed Web of Science ®Google Scholar
• Nimer SD. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. J. Clin. Oncol. 24(16), 2576–2582 (2006).
   PubMed Web of Science ®Google Scholar
• Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 251(5474), 437–438 (1974).
   PubMed Web of Science ®Google Scholar
• Van den Berghe H, Michaux L. 5q-, twenty-five years later: a synopsis. Cancer Genet. Cytogenet. 94(1), 1–7 (1997).
   PubMed Web of Science ®Google Scholar
• Mathew P, Tefferi A, Dewald GW et al. The 5q- syndrome: a single-institution study of 43 consecutive patients. Blood 81(4), 1040–1045 (1993).
   PubMed Web of Science ®Google Scholar
• Morrissette JJD, de Chadaravian JP, Kolb EA. Familial mosaic monosomy 7 syndrome. In: Gene Reviews. Pagon RA, Dolan CR (Eds). University of Washington, Seattle, WA, USA (1993).
   Google Scholar
• Luna-Fineman S, Shannon KM, Lange BJ. Childhood monosomy 7: epidemiology, biology, and mechanistic implications. Blood 85(8), 1985–1999 (1995).
   PubMed Web of Science ®Google Scholar
• Aricò M, Biondi A, Pui CH. Juvenile myelomonocytic leukemia. Blood 90(2), 479–488 (1997).
   PubMed Web of Science ®Google Scholar
• Jary L, Mossafa H, Fourcade C, Genet P, Pulik M, Flandrin G. The 17p-syndrome: a distinct myelodysplastic syndrome entity? Leuk. Lymphoma 25(1–2), 163–168 (1997).
   PubMed Web of Science ®Google Scholar
• Pedersen B. MDS and AML with trisomy 8 as the sole chromosome aberration show different sex ratios and prognostic profiles: a study of 115 published cases. Am. J. Hematol. 56(4), 224–229 (1997).
   PubMed Web of Science ®Google Scholar
• Olney HJ, Le Beau MM. The cytogenetics of myelodysplastic syndromes. Best Pract. Res. Clin. Haematol. 14(3), 479–495 (2001).
   PubMed Web of Science ®Google Scholar
• Gore SD, Warlick E. Myelodysplastic syndromes: pathophysiology. In: Leukemias: Principles and Practice of Therapy. Faderl S and Kantarjian H (Eds). Wiley–Blackwell, Oxford, UK, 77–86 (2010).
   Google Scholar
• Kohlmann A, Grossmann V, Klein HU et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J. Clin. Oncol. 28(24), 3858–3865 (2010).
   PubMed Web of Science ®Google Scholar
• Issa JP. Epigenetic changes in the myelodysplastic syndrome. Hematol. Oncol. Clin. North Am. 24(2), 317–330 (2010).
   PubMed Web of Science ®Google Scholar
• Feng J, Kim ST, Liu W et al. An integrated analysis of germline and somatic, genetic and epigenetic alterations at 9p21.3 in glioblastoma. Cancer 118(1), 232–240 (2012).
   PubMed Web of Science ®Google Scholar
• Cechova H, Lassuthova P, Novakova L et al. Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia. Neoplasma 59(2), 168–174 (2012).
   PubMed Web of Science ®Google Scholar
• Langemeijer SM, Kuiper RP, Berends M et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 41(7), 838–842 (2009).
   PubMed Web of Science ®Google Scholar
• Delhommeau F, Dupont S, Della Valle V et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360(22), 2289–2301 (2009).
   PubMed Web of Science ®Google Scholar
• Thol F, Friesen I, Damm F et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J. Clin. Oncol. 29(18), 2499–2506 (2011).
   PubMed Web of Science ®Google Scholar
• Rio-Machín A, Menezes J, Maiques-Diaz A et al. Abrogation of RUNX1 gene expression in de novo myelodysplastic syndrome with t(4;21)(q21;q22). Haematologica 97(4), 534–537 (2012).
   PubMedGoogle Scholar
• Rund D, Ben-Yehuda D. Therapy-related leukemia and myelodysplasia: evolving concepts of pathogenesis and treatment. Hematology 9(3), 179–187 (2004).
   PubMedGoogle Scholar
• Raza A, Qawi H, Mehdi M, Mumtaz M, Galili N. Translational research in myelodysplastic syndromes. Rev. Clin. Exp. Hematol. 8(2), E2 (2004).
   Google Scholar
• Schlegelberger B, Göhring G, Thol F, Heuser M. Update on cytogenetic and molecular changes in myelodysplastic syndromes. Leuk. Lymphoma 53(4), 525–536 (2012).
   PubMed Web of Science ®Google Scholar
• van Leeuwen FE. Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment. Baillieres Clin. Haematol. 9(1), 57–85 (1996).
   PubMedGoogle Scholar
• Pedersen-Bjergaard J, Larsen SO. Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin’s disease. N. Engl. J. Med. 307(16), 965–971 (1982).
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Philip P, Larsen SO, Jensen G, Byrsting K. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood 76(6), 1083–1091 (1990).
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Hawk K, Elias J et al. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Presented at: 53rd American Society of Hematology Meeting. San Diego, CA, USA, 10–13 December 2011.
   Google Scholar
• Aksoy M, Dincol K, Akgun T et al. The hematological effects of chronic benzene poisoning in 217 workers. Br. J. Ind. Med. 28(3), 296–302 (1971).
   PubMedGoogle Scholar
• Björk J, Albin M, Mauritzson N, Strömberg U, Johansson B, Hagmar L. Smoking and myelodysplastic syndromes. Epidemiology 11(3), 285–291 (2000).
   PubMed Web of Science ®Google Scholar
• Strom SS, Gu Y, Gruschkus SK, Pierce SA, Estey EH. Risk factors of myelodysplastic syndromes: a case–control study. Leukemia 19(11), 1912–1918 (2005).
   PubMed Web of Science ®Google Scholar
• Catenacci DV, Schiller GJ. Myelodysplasic syndromes: a comprehensive review. Blood Rev. 19(6), 301–319 (2005).
   PubMed Web of Science ®Google Scholar
• Bennett JM, Kaminski MS, Leonard JP et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 105(12), 4576–4582 (2005).
   PubMed Web of Science ®Google Scholar
• Sieglová Z, Zilovcová S, Cermák J et al. Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis? Leuk. Res. 28(10), 1013–1021 (2004).
   PubMed Web of Science ®Google Scholar
• Vas V, Senger K, Dörr K, Niebel A, Geiger H. Aging of the microenvironment influences clonality in hematopoiesis. PLoS ONE 7(8), e42080 (2012).
   PubMedGoogle Scholar
• Swierczek SI, Agarwal N, Nussenzveig RH et al. Hematopoiesis is not clonal in healthy elderly women. Blood 112(8), 3186–3193 (2008).
   PubMed Web of Science ®Google Scholar
• Chen H, Sandler DP, Taylor JA et al. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet 347(8997), 295–297 (1996).
   PubMed Web of Science ®Google Scholar
• Aul C, Giagounidis A, Germing U, Ganser A. Evaluating the prognosis of patients with myelodysplastic syndromes. Ann. Hematol. 81(9), 485–497 (2002).
   PubMed Web of Science ®Google Scholar
• Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 333(19), 1253–1258 (1995).
   PubMed Web of Science ®Google Scholar
• Germing U, Neukirchen J, Haas R. The epidemiology of myelodysplastic syndromes. Clin. Leuk. 2, 34–38 (2008).
   Google Scholar
• Germing U, Aul C, Niemeyer CM, Haas R, Bennett JM. Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Ann. Hematol. 87(9), 691–699 (2008).
   PubMed Web of Science ®Google Scholar
• Foran JM, Shammo JM. Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes. Am. J. Med. 125(7 Suppl.), S6–S13 (2012).
   PubMed Web of Science ®Google Scholar
• Khan AM. Why are myelodysplastic syndromes unrecognized and underdiagnosed? A primary care perspective. Am. J. Med. 125(7 Suppl.), S15–S17 (2012).
   Google Scholar
• May SJ, Smith SA, Jacobs A, Williams A, Bailey-Wood R. The myelodysplastic syndrome: analysis of laboratory characteristics in relation to the FAB classification. Br. J. Haematol. 59(2), 311–319 (1985).
   PubMed Web of Science ®Google Scholar
• Ríos A, Cañizo MC, Sanz MA et al. Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors. Br. J. Haematol. 75(1), 26–33 (1990).
   PubMed Web of Science ®Google Scholar
• Tricot G, Vlietinck R, Boogaerts MA et al. Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis. Br. J. Haematol. 60(1), 19–32 (1985).
   PubMed Web of Science ®Google Scholar
• Orazi A, Czader MB. Myelodysplastic syndromes. Am. J. Clin. Pathol. 132(2), 290–305 (2009).
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 87(7), 692–701 (2012).
   PubMed Web of Science ®Google Scholar
• Aul C, Germing U. [Myelodysplastic syndromes]. Internist (Berl.) 39(11), 1168–1180 (1998).
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120(12), 2454–2465 (2012).
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6), 2079–2088 (1997).
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Shan J, Faderl S et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 22(3), 538–543 (2008).
   PubMed Web of Science ®Google Scholar
• Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the acute leukaemias. French–American–British (FAB) co-operative group. Br. J. Haematol. 33(4), 451–458 (1976).
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100(7), 2292–2302 (2002).
   PubMed Web of Science ®Google Scholar
• Malcovati L, Porta MG, Pascutto C et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J. Clin. Oncol. 23(30), 7594–7603 (2005).
   PubMed Web of Science ®Google Scholar
• Malcovati L, Nimer SD. Myelodysplastic syndromes: diagnosis and staging. Cancer Control 15(Suppl.), 4–13 (2008).
   PubMedGoogle Scholar
• Verburgh E, Achten R, Louw VJ et al. A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification. Leukemia 21(4), 668–677 (2007).
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Stone RM, Zahrieh D et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 18(4), 809–816 (2004).
   PubMed Web of Science ®Google Scholar
• Sekeres MA. How to manage lower-risk myelodysplastic syndromes. Leukemia 26(3), 390–394 (2012).
   PubMed Web of Science ®Google Scholar
• Jansen AJ, Essink-Bot ML, Beckers EA, Hop WC, Schipperus MR, Van Rhenen DJ. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br. J. Haematol. 121(2), 270–274 (2003).
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Hofbauer LC, Ehninger G, Hölig K. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. Leuk. Res. 36(5), 525–536 (2012).
   PubMed Web of Science ®Google Scholar
• Hellström-Lindberg E, Ahlgren T, Beguin Y et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized Phase II study and long-term follow-up of 71 patients. Blood 92(1), 68–75 (1998).
   PubMed Web of Science ®Google Scholar
• Hellström-Lindberg E. Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents. Hematology Am. Soc. Hematol. Educ. Program 161–166 (2005).
   PubMedGoogle Scholar
• Hellström-Lindberg E, Willman C, Barrett AJ, Saunthararajah Y. Achievements in understanding and treatment of myelodysplastic syndromes. Hematology Am. Soc. Hematol. Educ. Program 110–132 (2000).
   PubMedGoogle Scholar
• Hellström-Lindberg E. Management of anemia associated with myelodysplastic syndrome. Semin. Hematol. 42(2 Suppl. 1), S10–S13 (2005).
   PubMed Web of Science ®Google Scholar
• Malcovati L, Della Porta MG, Strupp C et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 96(10), 1433–1440 (2011).
   PubMed Web of Science ®Google Scholar
• Hellström-Lindberg E, Negrin R, Stein R et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br. J. Haematol. 99(2), 344–351 (1997).
   PubMed Web of Science ®Google Scholar
• Hellström-Lindberg E. Approach to anemia associated with myelodysplastic syndromes. Curr. Hematol. Rep. 2(2), 122–129 (2003).
   PubMedGoogle Scholar
• Brechignac S, Hellström-Lindberg E, Bowen DT, DeWitte TM, Cazzola M, Fenaux P. Quality of life and economic impact of red blood cell (RBC) transfusions on patients with myelodysplastic syndromes (MDS). Blood 104(11), Abstract 4716 (2004).
   Google Scholar
• Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 91(12), 1588–1590 (2006).
   PubMed Web of Science ®Google Scholar
• Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood 114(26), 5251–5255 (2009).
   PubMed Web of Science ®Google Scholar
• Gilstad CW. Anaphylactic transfusion reactions. Curr. Opin. Hematol. 10(6), 419–423 (2003).
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Young NS, Gattermann N. Myelodysplastic syndromes. Hematology Am. Soc. Hematol. Educ. Program 136–161 (2002).
   PubMedGoogle Scholar
• Greenberg PL. Myelodysplastic syndromes: iron overload consequences and current chelating therapies. J. Natl. Compr. Canc. Netw. 4(1), 91–96 (2006).
   PubMedGoogle Scholar
• Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann. NY Acad. Sci. 850, 191–201 (1998).
   PubMed Web of Science ®Google Scholar
• Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 102(7), 2670–2677 (2003).
   PubMed Web of Science ®Google Scholar
• Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk. Res. 31(Suppl. 3), S2–S6 (2007).
   PubMed Web of Science ®Google Scholar
• Takatoku M, Uchiyama T, Okamoto S et al. The negative impact of iron overload on morbidity/mortality in Japanese patients with transfusion-dependent myelodysplastic syndromes and aplastic anemia: a retrospective survey. Book Abstr. Int. BioIron Soc. Abstract 112 (2007).
   Google Scholar
• Nemeth E, Tuttle MS, Powelson J et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306(5704), 2090–2093 (2004).
   PubMed Web of Science ®Google Scholar
• Nemeth E, Ganz T. Hepcidin and iron-loading anemias. Haematologica 91(6), 727–732 (2006).
   PubMed Web of Science ®Google Scholar
• Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu. Rev. Nutr. 26, 323–342 (2006).
   PubMed Web of Science ®Google Scholar
• Breda L, Ghoti H, Rivella S, Rechavi G, Cabatchnik I. Expression of genes regulating iron metabolism in hepatocyte cell-line HepG2 induced by sera from MDS patients. Blood 110, 4612 (2007).
   Google Scholar
• Malcovati L, Della Porta MG, Laarakkers CM et al. Erythroid activity, transfusion iron overload, and hepcidin levels in patients with myelodysplastic syndrome. Blood 112(11), Abstract 2676 (2008).
   PubMedGoogle Scholar
• Leitch HA. Controversies surrounding iron chelation therapy for MDS. Blood Rev. 25(1), 17–31 (2011).
   PubMed Web of Science ®Google Scholar
• Leitch HA. Improved survival in myelodysplastic syndromes patients receiving iron chelation therapy. Leuk. Res. 31(Suppl. 1), S15 (2007).
   Google Scholar
• Leitch HA, Leger CS, Goodman TA et al. Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clin. Leuk. 2(3), 205–211 (2008).
   Google Scholar
• Kouraklis A, Symeonidis A, Galanopoulos A et al. Iron chelation treatment in patients with myelodysplastic syndromes (MDS): the experience of the Hellenic MDS Study Group. Leuk. Res. 33(Suppl. 1), S119–S120 (2009).
   Google Scholar
• Cermak J, Kacirkova P, Mikulenkova D, Michalova K. Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts. Leuk. Res. 33(11), 1469–1474 (2009).
   PubMed Web of Science ®Google Scholar
• Pereira A, Nomdedeu M, Aguilar JL et al. Transfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support. Am. J. Hematol. 86(3), 245–250 (2011).
   PubMed Web of Science ®Google Scholar
• Sanz G, Nomdedeu B, Such E et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Blood 112(11), Abstract 640 (2008).
   Google Scholar
• Sallmyr A, Fan J, Rassool FV. Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Lett. 270(1), 1–9 (2008).
   PubMed Web of Science ®Google Scholar
• Pullarkat V, Blanchard S, Tegtmeier B et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 42(12), 799–805 (2008).
   PubMed Web of Science ®Google Scholar
• Pullarkat V. Iron overload in patients undergoing hematopoietic stem cell transplantation. Adv. Hematol. 2010, Abstract 345756 (2010).
   PubMedGoogle Scholar
• Leitch HA. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk. Res. 31 (Suppl. 3), S7–S9 (2007).
   PubMed Web of Science ®Google Scholar
• Leitch HA, Vickars LM. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron? Hematology Am. Soc. Hematol. Educ. Program 664–672 (2009).
   PubMedGoogle Scholar
• Wood JC, Enriquez C, Ghugre N et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 106(4), 1460–1465 (2005).
   PubMed Web of Science ®Google Scholar
• Wood JC. Magnetic resonance imaging measurement of iron overload. Curr. Opin. Hematol. 14(3), 183–190 (2007).
   PubMed Web of Science ®Google Scholar
• Di Tucci AA, Matta G, Deplano S et al. Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica 93(9), 1385–1388 (2008).
   PubMed Web of Science ®Google Scholar
• Konen E, Ghoti H, Goitein O et al. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique. Am. J. Hematol. 82(11), 1013–1016 (2007).
   PubMed Web of Science ®Google Scholar
• Porter JB. Concepts and goals in the management of transfusional iron overload. Am. J. Hematol. 82(Suppl. 12), 1136–1139 (2007).
   PubMed Web of Science ®Google Scholar
• Raptis A, Duh MS, Wang ST et al. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices. Transfusion 50(1), 190–199 (2010).
   PubMed Web of Science ®Google Scholar
• Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk. Res. 27(2), 95–120 (2003).
   PubMed Web of Science ®Google Scholar
• Cabantchik ZI, Link G, Glickstein H et al. Deferasirox (Exjade®, ICL670): A journey into labile iron centers of living cardiomyocytes. Blood 106(11), Abstract 824 (2005).
   PubMedGoogle Scholar
• Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 102(1), 17–24 (2003).
   PubMed Web of Science ®Google Scholar
• Porter JB, Cohen A, Agaoglu L et al. Long-term effects of deferasirox (Exjade®, ICL670) on serum ferritin: outcome of dose adjustments in achieving maintenance or reduction in body iron stores. Blood 108(11), Abstract 1769 (2006).
   Google Scholar
• Porter JB. Deferasirox: an update. Hemoglobin 33(Suppl. 1), S70–S75 (2009).
   Google Scholar
• List AF, Baer MR, Steensma D et al. Deferasirox (ICL670; Exjade®) reduces serum ferritin (SF) and labile plasma iron (LPI) in patients with myelodysplastic syndromes (MDS). Blood 110(11), Abstract 1470 (2007).
   PubMedGoogle Scholar
• Schmid M, Guerci-Bresler A, Della Porta M et al. Deferasirox (Exjade®) is effective and well tolerated in chelation-naive and previously chelated patients with transfusion-dependent myelodysplastic syndromes (MDS). Blood 114(22), Abstract 3806 (2009).
   PubMedGoogle Scholar
• Gattermann N, Finelli C, Porta MD et al.; EPIC study investigators. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk. Res. 34(9), 1143–1150 (2010).
   PubMed Web of Science ®Google Scholar
• Porter JB, Elalfy M, Aydinok Y et al. Efficacy and safety of deferasirox in patients with baseline liver iron concentration (LIC) <7 or =7 mg Fe/g dw: Results of EPIC liver magnetic resonance imaging (MRI) substudy. Haematologica 95(Suppl. 2), Abstract 1823 (2010).
   PubMedGoogle Scholar
• Greenberg PL, Koller CA, Glynos T, Paley C, Schiffer C. Change in liver iron concentration (LIC), serum ferritin (SF) and labile plasma iron (LPI) over 1 year of deferasirox (Exjade®) therapy in a cohort of patients with MDS. Leuk. Res. 33(Suppl. 1), S120 (2009).
   Google Scholar
• Bennett JM; MDS Foundation’s Working Group on Transfusional Iron Overload. Consensus statement on iron overload in myelodysplastic syndromes. Am. J. Hematol. 83(11), 858–861 (2008).
   PubMed Web of Science ®Google Scholar
• Gattermann N. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int. J. Hematol. 88(1), 24–29 (2008).
   PubMed Web of Science ®Google Scholar
• Wells RA, Leber B, Buckstein R et al. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. Leuk. Res. 32(9), 1338–1353 (2008).
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Attar E, Bennett JM et al.; National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J. Natl Compr. Canc. Netw. 9(1), 30–56 (2011).
   PubMed Web of Science ®Google Scholar
• Rose C, Brechignac S, Vassilief D et al.; GFM (Groupe Francophone des Myélodysplasies). Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). Leuk. Res. 34(7), 864–870 (2010).
   PubMed Web of Science ®Google Scholar
• Komrokji RS, Al Ali NH, Padron E, Lancet JE, List AF. Impact of iron chelation therapy on overall survival and AML transformation in lower risk MDS patients treated at the moffitt cancer center. Blood 118(21), Abstract 2776 (2011).
   Google Scholar
• Fox F, Kundgen A, Nachtkamp K et al. Matched-pair analysis of 186 MDS patients receiving iron chelation therapy or transfusion therapy only. Blood 114(22), Abstract 1747 (2009).
   Google Scholar
• Neukirchen J, Fox F, Kündgen A et al. Improved survival in MDS patients receiving iron chelation therapy – a matched pair analysis of 188 patients from the Düsseldorf MDS registry. Leuk. Res. 36(8), 1067–1070 (2012).
   PubMed Web of Science ®Google Scholar
• Lyons R, Marek BL, Sharma S et al. 24-month analysis of the impact of chelation on clinical outcomes in a 600 patient registry of lower-risk MDS patients. Blood 118(21), Abstract 2800 (2011).
   Google Scholar
• Messa E, Cilloni D, Saglio G. Iron chelation therapy in myelodysplastic syndromes. Adv. Hematol. 2010, 756289 (2010).
   PubMedGoogle Scholar
• Gattermann N, Finelli C, la Porta M et al. Hematologic responses with deferasirox therapy in transfusion-dependent myelodysplastic syndromes patients. Haematologica 97(9), 1364–1371 (2012).
   PubMed Web of Science ®Google Scholar
• Improta S, Villa MR, Volpe A et al. Iron overload in low-risk myelodysplastic syndromes (MDS): a multicentric study. Leuk. Res. 35(Suppl. 1), S141 (2011).
   Google Scholar
• Arrizabalaga B, del Canizo C, Remacha A, Sanz G, Villegas A. Guia clinica de quelacion del paciente con sindrome mielodisplasico [Clinical guide to chelation therapy for patients with myelodysplastic syndrome (Spanish Guidelines)]. Haematologica 93(Suppl. 1), 3–10 (2008).
   Google Scholar
• Suzuki T, Tomonaga M, Miyazaki Y et al. Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes. Int. J. Hematol. 88(1), 30–35 (2008).
   PubMed Web of Science ®Google Scholar
• Jensen PD, Heickendorff L, Pedersen B et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br. J. Haematol. 94(2), 288–299 (1996).
   PubMed Web of Science ®Google Scholar
• Gattermann N, Porter J, Lopes LF, Seymour J. Consensus statement on iron overload in myelodysplastic syndromes. Hematol. Oncol. Clin. North Am. 19(Suppl. 1), 18–25 (2005).
   Google Scholar
• Gattermann N. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Leuk. Res. 31(Suppl. 3), S10–S15 (2007).
   PubMed Web of Science ®Google Scholar
• Gattermann N. Chelation therapy in myelodysplastic syndrome: update from recent clinical trials with oral agents. Leuk. Res. 29(Suppl. 1), S18 (2005).
   Google Scholar
• Gattermann N, Schmid M, Della Porta M et al. Efficacy and safety of deferasirox (Exjade®) during 1 year of treatment in transfusion-dependent patients with myelodysplastic syndromes: results from EPIC trial. Blood 112(11), Abstract 633 (2008).
   Google Scholar
• Nolte F, Angelucci E, Beris P et al. Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox. Leuk. Res. 35(9), 1131–1135 (2011).
   PubMedGoogle Scholar
• Porter JB, Lin K-H, Habr D, Domokos G, Hmissi A, Thein SL. Deferasirox efficacy and safety for the treatment of transfusion-dependent iron overload in patients with a range of rare anemias. Blood 112(11), Abstract 1419 (2008).
   Google Scholar
• Schmid M, Cappellini MD, Porter JB et al. Safety of deferasirox (Exjade®) in myelodysplastic syndromes (MDS) and non-MDS patients with transfusional iron overload: a pooled analysis focusing on renal function. Blood 114(22), Abstract 1768 (2009).
   PubMedGoogle Scholar
• Chesi A, Rigourd S, Frederick A. Exjade^® (deferasirox), prescribing information. Novartis Pharma Stein AG, Stein, Switzerland (2010).
   Google Scholar
• Kantarjian H, Giles F, List A et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 109(9), 1705–1714 (2007).
   PubMed Web of Science ®Google Scholar
• Al Ameri A, Jabbour E, Garcia-Manero G et al. Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications. Clin. Lymphoma. Myeloma Leuk. 11(2), 237–241 (2011).
   PubMed Web of Science ®Google Scholar
• Neukirchen J, Blum S, Kuendgen A et al. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes. Eur. J. Haematol. 83(5), 477–482 (2009).
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Baer MR, Bennett JM et al. Myelodysplastic syndromes clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 4(1), 58–77 (2006).
   PubMedGoogle Scholar
• Kantarjian H, Fenaux P, Sekeres MA et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J. Clin. Oncol. 28(3), 437–444 (2010).
   PubMed Web of Science ®Google Scholar
• Corman SL, Mohammad RA. Eltrombopag: a novel oral thrombopoietin receptor agonist. Ann. Pharmacother. 44(6), 1072–1079 (2010).
   PubMed Web of Science ®Google Scholar
• Bowen D, Culligan D, Jowitt S et al.; UK MDS Guidelines Group. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br. J. Haematol. 120(2), 187–200 (2003).
   PubMed Web of Science ®Google Scholar
• Greenberg PL. The role of hematopoietic growth factors in the treatment of myelodysplastic syndromes. Int. J. Ped. Hem. Onc. 4, 231–238 (1997).
   Web of Science ®Google Scholar
• Hellström-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br. J. Haematol. 89(1), 67–71 (1995).
   PubMed Web of Science ®Google Scholar
• Casadevall N, Durieux P, Dubois S et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 104(2), 321–327 (2004).
   PubMed Web of Science ®Google Scholar
• Mannone L, Gardin C, Quarre MC et al.; Groupe Francais des Myelodysplasies. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a Phase II study. Br. J. Haematol. 133(5), 513–519 (2006).
   PubMed Web of Science ®Google Scholar
• Stasi R, Abruzzese E, Lanzetta G, Terzoli E, Amadori S. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann. Oncol. 16(12), 1921–1927 (2005).
   PubMed Web of Science ®Google Scholar
• Warlick ED, Smith BD. Myelodysplastic syndromes: review of pathophysiology and current novel treatment approaches. Curr. Cancer Drug Targets 7(6), 541–558 (2007).
   PubMed Web of Science ®Google Scholar
• Bowen D, Culligan D, Jacobs A. The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin. Br. J. Haematol. 77(3), 419–423 (1991).
   PubMed Web of Science ®Google Scholar
• Verhoef GE, Zachée P, Ferrant A et al. Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment. Ann. Hematol. 64(1), 16–21 (1992).
   PubMed Web of Science ®Google Scholar
• List A, Kurtin S, Roe DJ et al. Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl. J. Med. 352(6), 549–557 (2005).
   PubMed Web of Science ®Google Scholar
• Raza A, Reeves JA, Feldman EJ et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111(1), 86–93 (2008).
   PubMed Web of Science ®Google Scholar
• List AF, Dewald G, Bennett J et al. Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: results of the multicenter MDS-003 study. J. Clin. Oncol. 23(16 Suppl.), 5 (2005).
   PubMedGoogle Scholar
• List AF. Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS). Semin. Oncol. 32(4 Suppl. 5), S31–S35 (2005).
   Web of Science ®Google Scholar
• List A, Dewald G, Bennett J et al.; Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med. 355(14), 1456–1465 (2006).
   PubMed Web of Science ®Google Scholar
• Lenalidomide. MIMS Prescribing Guide. Haymarket Media Group, London, UK (2012).
   Google Scholar
• Chen C, Reece DE, Siegel D et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br. J. Haematol. 146(2), 164–170 (2009).
   PubMed Web of Science ®Google Scholar
• Adès L, Fenaux P. Updates on treatment strategies in myelodsplastic syndromes: immunomodulating drugs in myelodysplastic syndromes. Hematology 201, 556–560 (2011).
   Google Scholar
• Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br. J. Haematol. 99(3), 699–705 (1997).
   PubMed Web of Science ®Google Scholar
• Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J. Clin. Oncol. 26(15), 2505–2511 (2008).
   PubMed Web of Science ®Google Scholar
• Steensma DP, Dispenzieri A, Moore SB, Schroeder G, Tefferi A. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 101(6), 2156–2158 (2003).
   PubMed Web of Science ®Google Scholar
• Silverman LR, Holland JF, Demakos EP et al. Azacytidine (AzaC) in myelodysplastic syndromes (MDS), CALGB studies 8421 and 8921. Ann. Hematol. 68(Suppl. 12), 12 (1994).
   Google Scholar
• Sloand EM, Olnes MJ, Shenoy A et al. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J. Clin. Oncol. 28(35), 5166–5173 (2010).
   PubMed Web of Science ®Google Scholar
• Biesma DH, van den Tweel JG, Verdonck LF. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer 79(8), 1548–1551 (1997).
   PubMed Web of Science ®Google Scholar
• Santini V. Novel therapeutic strategies: hypomethylating agents and beyond. Hematology Am. Soc. Hematol. Educ. Program 2012, 65–73 (2012).
   PubMedGoogle Scholar
• Kaminskas E, Farrell A, Abraham S et al.; FDA. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin. Cancer Res. 11(10), 3604–3608 (2005).
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Santini V et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): Results of the AZA-001 Phase III study. Blood 110(11), Abstract 817 (2007).
   Google Scholar
• Fenaux P, Mufti GJ, Hellström-Lindberg E et al.; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, Phase III study. Lancet Oncol. 10(3), 223–232 (2009).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a Phase III randomized study. Cancer 106(8), 1794–1803 (2006).
   PubMed Web of Science ®Google Scholar
• Wijermans P, Lübbert M, Verhoef G et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter Phase II study in elderly patients. J. Clin. Oncol. 18(5), 956–962 (2000).
   PubMed Web of Science ®Google Scholar
• Naqvi K, Oh J, Garcia-Manero G, Pierce S, Suarez-Almazor ME. Comorbidities and prognosis of myelodysplastic syndromes. J. Clin. Oncol. (Meeting Abstracts) 27(15S), 7086 (2009).
   Google Scholar
• Itzykson R, Fenaux P. Optimizing hypomethylating agents in myelodysplastic syndromes. Curr. Opin. Hematol. 19(2), 65–70 (2012).
   PubMed Web of Science ®Google Scholar
• Wijermans PW, Luebbert M, Verhoef G. Low dose decitabine for elderly high risk MDS patients: who will respond? Blood 100(Suppl. 1), 96a (2002).
   PubMedGoogle Scholar
• Jabbour E, Garcia-Manero G, Batty N et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 116(16), 3830–3834 (2010).
   PubMed Web of Science ®Google Scholar
• Prebet T, Thepot S, Gore SD, Dreyfus F, Fenaux P, Vey N. Outcome of patients with low risk myelodysplasia after azacitidine treatment failure. Haematologica 98(2), e18–e19 (2012).
   Web of Science ®Google Scholar
• Greenberg PL. Current therapeutic approaches for patients with myelodysplastic syndromes. Br. J. Haematol. 150(2), 131–143 (2010).
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Tiu RV, Komrokji R et al. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood 120(25), 4945–4951 (2012).
   PubMed Web of Science ®Google Scholar
• Fenaux P, Giagounidis A, Selleslag D et al.; MDS-004 Lenalidomide del5q Study Group. A randomized Phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood 118(14), 3765–3776 (2011).
   PubMed Web of Science ®Google Scholar
• Capalbo S, Spinosa G, Franzese MG, Palumbo G. Early deferasirox treatment in a patient with myelodysplastic syndrome results in a long-term reduction in transfusion requirements. Acta Haematol. 121(1), 19–20 (2009).
   PubMed Web of Science ®Google Scholar
• Messa E, Cilloni D, Messa F, Arruga F, Roetto A, Saglio G. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol. 120(2), 70–74 (2008).
   PubMed Web of Science ®Google Scholar
• Messa E, Cilloni D, Messa F, Arruga F, Roetto A, Saglio G. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol. 120(2), 70–74 (2008).
   PubMed Web of Science ®Google Scholar
• Kikuchi S, Kobune M, Iyama S et al. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox. Free Radic. Biol. Med. 53(4), 643–648 (2012).
   PubMed Web of Science ®Google Scholar
• Rose C, Brechignac S, Vassilief D et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM. Blood 110(11), Abstract 249 (2007).
   Google Scholar
• Scott BL, Deeg HJ. Hemopoietic cell transplantation for the myelodysplastic syndromes. Arch. Immunol. Ther. Exp. (Warsz.) 53(4), 297–307 (2005).
   PubMed Web of Science ®Google Scholar
• Verbeek W, Ganser A. Evolving treatment options of myelodysplastic syndromes. Ann. Hematol. 80(9), 499–509 (2001).
   PubMed Web of Science ®Google Scholar
• de Lima M, Giralt S. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. Semin. Hematol. 43(2), 107–117 (2006).
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Appelbaum FR. Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Leuk. Res. 24(8), 653–663 (2000).
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Bornhäuser M, Germing U et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol. Blood Marrow Transplant. 14(11), 1217–1225 (2008).
   PubMed Web of Science ®Google Scholar
• Armand P, Kim HT, Cutler CS et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 109(10), 4586–4588 (2007).
   PubMed Web of Science ®Google Scholar
• Mahindra A, Bolwell B, Sobecks R et al. Elevated ferritin is associated with relapse after autologous hematopoietic stem cell transplantation for lymphoma. Biol. Blood Marrow Transplant. 14(11), 1239–1244 (2008).
   PubMed Web of Science ®Google Scholar
• Mahindra A, Bolwell B, Sobecks R et al. Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Br. J. Haematol. 146(3), 310–316 (2009).
   PubMed Web of Science ®Google Scholar
• Altès A, Remacha AF, Sureda A et al. Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. Bone Marrow Transplant. 29(12), 987–989 (2002).
   PubMed Web of Science ®Google Scholar
• Lim ZY, Fiaccadori V, Gandhi S et al. Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation. Leuk. Res. 34(6), 723–727 (2010).
   PubMed Web of Science ®Google Scholar
• Miceli MH, Dong L, Grazziutti ML et al. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant. 37(9), 857–864 (2006).
   PubMed Web of Science ®Google Scholar
• de Witte T. The role of iron in patients after bone marrow transplantation. Blood Rev. 22(Suppl. 2), S22–S28 (2008).
   PubMed Web of Science ®Google Scholar
• Brissot E, Savani BN, Mohty M. Management of high ferritin in long-term survivors after hematopoietic stem cell transplantation. Semin. Hematol. 49(1), 35–42 (2012).
   PubMed Web of Science ®Google Scholar
• Angelucci E, Muretto P, Lucarelli G et al. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. Blood 90(3), 994–998 (1997).
   PubMed Web of Science ®Google Scholar
• Franchini M, Gandini G, Veneri D et al. Efficacy and safety of phlebotomy to reduce transfusional iron overload in adult, long-term survivors of acute leukemia. Transfusion 44(6), 833–837 (2004).
   PubMed Web of Science ®Google Scholar
• Schmalzl F. The value of cytochemical investigations in the diagnosis of the myelodysplastic syndrome. In: Myelodysplastic Syndromes. Schmalzl F, Mufti GJ (Eds). Springer, Berlin, Germany, 44–50 (1992).
   Google Scholar
• Seo IS, Li CY, Yam LT. Myelodysplastic syndrome: diagnostic implications of cytochemical and immunocytochemical studies. Mayo Clin. Proc. 68(1), 47–53 (1993).
   PubMed Web of Science ®Google Scholar
• Valent P, Horny HP, Bennett JM et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk. Res. 31(6), 727–736 (2007).
   PubMed Web of Science ®Google Scholar
• van de Loosdrecht AA, Alhan C, Bene MC et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 94(8), 1124–1134 (2009).
   PubMed Web of Science ®Google Scholar
• Benesch M, Deeg HJ, Wells D, Loken M. Flow cytometry for diagnosis and assessment of prognosis in patients with myelodysplastic syndromes. Hematology 9(3), 171–177 (2004).
   PubMedGoogle Scholar
• Loken MR, van de Loosdrecht A, Ogata K, Orfao A, Wells DA. Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk. Res. 32(1), 5–17 (2008).
   PubMed Web of Science ®Google Scholar
• Coutinho LH, Geary CG, Chang J, Harrison C, Testa NG. Functional studies of bone marrow haemopoietic and stromal cells in the myelodysplastic syndrome (MDS). Br. J. Haematol. 75(1), 16–25 (1990).
   PubMed Web of Science ®Google Scholar
• Shih LY, Chiu WF, Lee CT. Diagnostic and prognostic values of in vitro culture growth patterns of marrow granulocyte-macrophage progenitors in patients with myelodysplastic syndrome. Leukemia 5(12), 1092–1098 (1991).
   PubMed Web of Science ®Google Scholar
• Bejar R, Levine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J. Clin. Oncol. 29(5), 504–515 (2011).
   PubMed Web of Science ®Google Scholar
• Ferriprox, MIMS Prescribing Guide. Haymarket Media Group, London, UK (2012).
   Google Scholar
• Exjade, MIMS Prescribing Guide. Haymarket Media Group, London, UK (2012).
   Google Scholar
• Deferiprone, MIMS Prescribing Guide. Haymarket Media Group, London, UK (2012).
   Google Scholar